drugset / Trial / NCT00006000
SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. SU5416 may stop the growth of solid tumors by stopping blood flow to the tumor. Combining SU5416 with chemotherapy may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of SU5416 plus irinotecan and cisplatin in treating patients who have advanced solid tumors.
Timeline
- Start
- 2000-08
- Primary completion
- —
- Completion
- 2004-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | Intravenous |
| Subject | Irinotecan | Small molecule | — | Intravenous |
| Subject | semaxanib | Small molecule | — | Intravenous |